<DOC>
	<DOCNO>NCT00840177</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , idarubicin cytarabine , work different way stop growth cancer cell , either kill cell stop dividing . Pravastatin may stop growth cancer cell block enzymes need cell growth . Pravastatin may also help idarubicin cytarabine work well make cancer cell sensitive drug . Giving idarubicin cytarabine together pravastatin may kill cancer cell . PURPOSE : This phase II trial study well give idarubicin cytarabine together pravastatin work treat patient relapse acute myeloid leukemia .</brief_summary>
	<brief_title>S0919 Idarubicin , Cytarabine , Pravastatin Treating Patients With Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - To test whether complete remission ( CR ) rate ( include CR incomplete recovery ) patient relapse acute myeloid leukemia treat idarubicin cytarabine combination pravastatin sufficiently high warrant phase III investigation . - To estimate relapse-free survival overall survival rate patient . - To estimate frequency severity toxicity regimen patient . - To evaluate , preliminary manner , whether pre-study cytogenetic feature correlate response patient . OUTLINE : This multicenter study . - Induction therapy : Patients receive oral pravastatin daily day 1-8 , idarubicin IV 10-15 minute day 4-6 , cytarabine IV continuously day 4-7 . Patients achieve complete remission proceed consolidation therapy . - Consolidation therapy : Beginning 30-60 day start induction therapy , patient receive oral pravastatin daily day 1-6 idarubicin IV 10-15 minute cytarabine IV continuously day 4 5 . Treatment repeat approximately every 5 week 2 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Cohort 1 ( MDS transform AML ) open accrual Cohort 2 ( relapsed/refractory AML ) permanently close accrual DISEASE CHARACTERISTICS : For patient registered relapsed/refractory ( Cohort 2 ) , morphologically confirm diagnosis acute myeloid leukemia ( AML ) Patient register MDS transform AML cohort ( Cohort 1 ) patient must previous morphologically confirm diagnosis MDS/CMML . Patients may receive previous nonintensive therapy ( : azacitadine , decitabine , lowdose cytarabine , lenalidomide ) give treatment MDS/CMML ( 20 % blast ) . At time registration , patient must morphologically confirm diagnosis AML . Patients acute promyelocytic leukemia ( i.e. , APL , FAB M3 ) blastic transformation chronic myelogenous leukemia eligible Patients mus receive autologous allogeneic stem cell transplant . Patients relapsed/refractory AML cohort ( Cohort 2 ) must : Have receive ≥ 1 prior chemotherapy regimen AML Any type prior chemotherapy allow Administration hydroxyurea control high WBC prior , , registration permit Relapse must document bone marrow examination demonstrate &gt; 5 % blast bone marrow attributable another cause Patient must receive chemo within 14 day prior registration Primary refractory patient eligible , Day 14 previous chemo regimen , significant residual disease . Patients receive hypomethylating agent low dose therapy Induction consider primary refractory study eligible . Relapsed patient must achieve complete remission ( CR ) CR incomplete blood count recovery last &lt; 6 month last induction regimen No clinical evidence leptomeningeal disease Pretreatment ( collect within 28 day registration ) cytogenetics must perform patient . Patients must complete history physical exam within 28 day prior registration . PATIENT CHARACTERISTICS : No symptomatic congestive heart failure , coronary artery disease , cardiomyopathy , uncontrolled arrhythmia Ejection fraction ≥ 45 % echocardiogram MUGA scan within 28 day prior registration ( within 14 day prior registration patient receive anthracycline 28 day window ) Zubrod performance status 02 Serum creatinine ≤ 2.0 time upper limit normal ( ULN ) Total bilirubin ≤ 2.0 time ULN ( unless elevation primarily due elevate unconjugated hyperbilirubinemia secondary Gilbert 's syndrome hemolysis AND due liver dysfunction ) AST ALT ≤ 3.0 time ULN Not pregnant nursing negative pregnancy test within 14 day prior registration . Females childbearing potential must agree use effective contraception No HIV positivity unless follow criterion meet : No history AIDSdefining event CD4 count ≥ 500/mm³ Viral load &lt; 25,000 copy ( &lt; 50 copy combination antiretroviral therapy ) Not receive zidovudine stavudine part combination antiretroviral therapy No uncontrolled systemic fungal , bacterial , viral , infection , define exhibit ongoing signs/symptoms related infection improvement despite appropriate antibiotic treatment Patients prior malignancy ( AML MDS/CMML ) eligible provide patient remission malignancy least 6 month prior registration . Except AML MDS treatment , treatment related toxicity must resolve .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
</DOC>